In an effort to develop and commercialize central nervous system disorder therapies, such as Alzheimer’s disease and schizophrenia, Vanderbilt University’s Warren Center for Neuroscience Drug Discovery (VCNDD) entered into an exclusive worldwide licensing and...
Central Nervous System
Category
Promising Interim Results for Investigational Combination Therapies Treating Newly Diagnosed Glioblastoma
The diagnosis of Glioblastoma, an aggressive tumor of the central nervous system, changes life as we know it. Upon the initial news and with the flurry of medical activity comes a recognition for those suffering with the cancer (and their loved ones) that life will...
Vanderbilt University Inks Deal Worth up to $525m with ACADIA Pharmaceutics for CNS Drug License
Vanderbilt University inked a deal with publicly traded ACADIA Pharmaceuticals (ACAD) to enter into an exclusive worldwide license agreement to develop and commercialize novel drug candidates targeting the muscarinic MI receptor with the potential to treat a range of...
Vanderbilt University Secures $20m from William K. Warren Foundation to Further Treatments for Brain Disorders
Vanderbilt University received $20 million from the William K Warren Foundation located in Tulsa, Oklahoma to establish the Warren Center for Neuroscience Drug Discovery. This adds to the Center for Neuroscience Drug Discovery, led by co-directors Craig Lindsley and...
First Alzheimer’s Drug Approved in China Comes to U.S. Clinical Trials as FDA Approves China’s Green Valley Pharma’s IND
Toward the end of last year, TrialSite News introduced the first approved Alzheimer’s disease (AD) drug approved in years; Chinese regulators approved the drug Oligomannate (GV-971) made by Green Valley Pharmaceuticals. They made good on their promise to hit America...
Yale Study Reveals Successful Technique to Reduce Opioid Addiction
Yale School of Medicine clinician-researchers have developed a novel approach for helping patients on long-term painkillers reduce opioid use, as well as unwanted side effects such as fatigue and grogginess less the most dreadful part of kicking the habit—withdrawal...
Young Investigators Profile: Virginia Tech’s Christopher Liao Pursues a Better Understanding of Alzheimer’s Disease
Virginia Tech’s Christopher Liao, a four-year Carilion School of Medicine student, developed novel insight into Alzheimer’s disease as part of his graduate research project. Specifically looking for how the neurodegenerative disease impacted blood vessels in the brain...
Michigan State University a Hub of Alzheimer’s Research in Western Michigan with Influence Beyond
A Michigan State University (MSU) is researching a cure for Alzheimer’s disease. Located at the MSU Grand Rapids Research Center, the Alzheimer’s Alliance conducts a series of clinical trials, connecting people who have the disease with researchers trying to stop it....
MRC London Institute of Medical Sciences with Breakthrough in Understanding Schizophrenia
Researchers from the Medical Research Council (MRC) London Institute of Medical Sciences report that based on a recent study powered by advanced scanning technology, they are able to associate lower levels of a protein in connection with neurons in schizophrenia...
FDA Approves Lemborexant (Dayvigo) for Insomnia Disorder—A Growing Problem
Dayvigo (lemborexant), developed and sponsored by Eisai, was approved by the Food and Drug Administration (FDA) for the treatment of insomnia characterized by difficulties with sleep onset or sleep maintenance in adult patients. The approval of this new orexin...
CITrials: A Site for Mental Health Clinical Research in Diverse Southern California
Sponsors that are planning central nervous system-focused clinical studies with diverse patient participation in California should consider CITrials. A Southern California-based clinical research site, CITrials conducts full-service on behalf of a myriad of clinical...
University of Iowa Receives Grant in Quest to Unlock a Potential Huntington’s Disease Cure
University of Iowa recently received a five-year, $18 million grant from the National Institute of Neurological Disorders and Stroke to continue an exciting, decade-long research initiative centering on unlocking a potential cure for Huntington’s disease. Led by...
West Point’s Keller Army Community Hospital Division I First to Enroll Subject in Military-Sponsored Clinical Trial
The Keller Army Community Hospital Division I Sports Physical Therapy Fellowship Project #13 Team was the first team within the Musculoskeletal Injury Rehabilitation Research for Operational Readiness (MIRROR) group at the Uniformed Services University to enroll a...
Stanford Researchers Pre-Clinical Research Reveals Party Drug’s Therapeutic and Addictive Qualities
Stanford University School of Medicine investigators have successfully distinguished the molecular pathway responsible for Methylenedioxy-methamphetamine (MDMA aka ecstasy) abuse potential from the one behind its propensity to make people feel sociable. MDMA is a mind...
Stanford Researchers Study Reveals Need for Better Understanding of Clinical Trial Risks
Stanford University researchers study concludes that clinical trials can offer patients with Huntington’s disease (HD) hope when there are no treatments available despite unknowns whether the therapy will work or is safe. The study results show that although the HD...
Chung-Ang University Research Team Study Makes Connection between ADHD & Internet Gaming Disorder
Korea’s Chung-Ang University Hospital investigators from its Online Game Clinic and Research Center conducted a study to conclude that attention deficit hyperactivity disorder (ADHD) is a common comorbidity with Internet Gaming Disorder (IDG), an apparent condition...
Massachusetts General Hospital First to Enroll Adults with Down Syndrome in New Nationwide Study Supported by LuMind IDSC Foundation
The Massachusetts General Hospital (MGH) Down Syndrome Program was the first approved clinical investigational site in the first clinical trial in the Down Syndrome—Clinical Trials Network (DS-CTN) supported by LuMind IDSC Foundation. MGH is enrolling adults with Down...
Nationwide Clinical Investigational Site Consolidation Continues with CNS-Focused Consolidation Funded by Bison Capital Partners
In yet another private equity-backed consolidation move in the clinical research site market, private equity made a power move again, this time underwriting a new central nervous system (CNS)-focused site organization roll-up called Apex Innovative Sciences (Apex)....
JEM Research Institute Seeks Participants for Sunovion’s Investigational Treatment for Parkinson’s Disease Psychosis Clinical Trial
Clinical investigative Site JEM Research Institute, based in Atlantis, Florida, seeks participants for a clinical trial evaluating an investigational medication in people diagnosed with Parkinson’s disease who are experiencing symptoms such as seeing and hearing...
MSU & USF Seeks Participants for the PACT Study: A Clinical Trials Focusing on Dementia Treatment
Michigan State University (MSU), along with sponsor University of South Florida, are seeking participants for a dementia clinical trial known as the PACT study. With an increasing number of aging Baby Boomers, dementia becomes an ever growing (and costly) problem. The...